CLDA: Clinical Data Named For Second Year in Row as One of New England's Fastest Growing Life Sciences Companies in Deloitte's Technology Fast 50 Prog

Clinical Data, Inc. (NASDAQ: CLDA) has been named for the second year in a row to Deloitte's prestigious Technology Fast 50 Program for New England, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2001-2005.

Drew Fromkin, President and CEO of Clinical Data, credits the company's acquisition strategy for the company's robust 336 percent revenue growth rate from 2001-2005. Fromkin said, "We are very pleased to be included for two years in a row in the Fast 50 and we are gratified that our business strategy to capitalize on anticipated growth opportunities in pharmacogenomics, pharmacogenetics and related services has begun to deliver the results we anticipated. We believe these initiatives including our focus on Therapeutic Diagnostics(TM), genetic tests that determine how individuals will respond to specific drugs, will assist us in growing the company further in 2006 and beyond. We are proud to be named one of the fastest growing technology companies in New England along with an impressive list of other recipients of this designation."

Clinical Data's increase in revenues of 336 percent from 2001 to 2005 resulted in a 40 ranking in the Technology Fast 50 for New England. The average increase in revenues among companies who made the Technology Fast 50 for this region was 1,825 percent.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are eligible to be entered into the Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive pharmacogenomics and molecular biology services and genetic tests to improve patient care, is organized under three worldwide divisions: Cogenics(TM); PGxHealth(TM), and Vital Diagnostics(TM). Cogenics consolidates certain of the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA, to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development. PGxHealth builds upon the existing assets and know-how of Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth also develops, validates and commercializes novel Therapeutic Diagnostics(TM) to improve patient care, and has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.